Skip to main content

Latest stock market podcasts

From the helm: Immutep’s (ASX:IMM) Executive Director & CEO Marc Voigt

Sophia Mavridis
April 6, 2022

In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep’s (ASX:IMM) Executive Director and CEO, Marc Voigt.

Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.

In this video Marc discusses:

  • (0:40) What IMM does and its key strength in the market
  • (1:27) The impact of the FDA’s recent feedback on its lead product
  • (2:53) IMM’s collaborations with big pharma names like Pfizer & Merck
  • (4:03) When to expect data from its current clinical trials
  • (5:10) What’s coming up for IMM

Note: This interview was filmed on 22 March 2022.

Morning Bell 1 February

Bell Direct
February 1, 2024

Morning Bell 31 January

Bell Direct
January 31, 2024

Morning Bell 30 January

Bell Direct
January 30, 2024

Morning Bell 29 January

Bell Direct
January 29, 2024

Morning Bell 25 January

Bell Direct
January 25, 2024

Morning Bell 24 January

Bell Direct
January 24, 2024

Morning Bell 23 January

Bell Direct
January 23, 2024

Morning Bell 22 January

Bell Direct
January 22, 2024

Weekly Wrap 19 January

Bell Direct
January 19, 2024

Morning Bell 19 January

Bell Direct
January 19, 2024

Morning Bell 18 January

Bell Direct
January 18, 2024